Can-Fite BioPharma Ltd.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $405.0K | $674.0K | $743.0K | $810.0K | $853.0K | $763.0K | $2.0M | $3.8M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $6.7M | $5.8M | $6.0M | $7.8M | $9.9M | $12.0M | $11.0M | $6.1M |
| SG&A Expense | $3.7M | $3.0M | $3.0M | $263.0K | $466.0K | $317.0K | $3.1M | $3.2M |
| Operating Income | $-10.0M | $-8.1M | $-8.2M | $-10.1M | $-12.8M | $-14.1M | $-12.0M | $-5.4M |
| Operating Margin | -2,456.8% | -1,206.2% | -1,103.0% | -1,246.4% | -1,505.5% | -1,853.1% | -590.9% | -141.7% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-9.8M | $-7.9M | $-7.6M | $-10.2M | $-12.6M | $-14.4M | $-12.6M | $-6.6M |
| Income Tax Expense | — | — | — | — | — | — | — | $4.0K |
| Net Income | $-9.8M | $-7.9M | $-7.6M | $-10.2M | $-12.6M | $-14.4M | $-12.6M | $-6.6M |
| Net Margin | -2,426.7% | -1,169.1% | -1,027.5% | -1,255.9% | -1,478.9% | -1,892.9% | -621.3% | -172.0% |
| EPS (Basic) | $-5.97 | $-10.86 | $-17.92 | $-0.01 | $-0.03 | $-0.04 | $-0.14 | $-0.17 |
| EPS (Diluted) | $-5.97 | $-10.86 | $-17.92 | $-0.01 | $-0.03 | $-0.04 | $-0.14 | $-0.17 |
| Shares Outstanding (Basic) | 1.6M | 2.18B | 1.28B | 815.7M | 553.1M | 358.4M | 120.7M | 40.4M |
| Shares Outstanding (Diluted) | 1.6M | 2.18B | 1.28B | 815.7M | 553.1M | 358.4M | 120.7M | 40.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |